TICKERNERD
Menu
AYTUAYTUHealthcare · Drug Manufacturers - Specialty & Generic

AYTU Stock Forecast: Aytu Biopharma, Inc. Price Predictions for 2026-2027

Last close, 7 Oct 2026
$2.05
0.00% on the day

The 3 Wall Street analysts covering Aytu Biopharma, Inc. hold a median 12-month price target of $7 — +241.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 88 of 100 as at 7 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$22.3M
Ticker Nerd rank
88 / 100
Median analyst target
$7.00
Analysts covering
3
Revenue$12.4M−32.7% y/y
Operating income−$4.1M
Net income−$5.6M
Free cash flow−$4.2M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.2%
1M
−7.2%
YTD
−21.2%
1Y
−13.1%
From 52W high
−29.3%
From 52W low
+5.7%
$1.94
$2.90
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AYTU stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Aytu Biopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 7 Oct 2026
88 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
92
Accruals
89
Size
87
Value
80
Quality
78
Issuance
61
Growth
56
Momentum
46
Revisions
39

Volatility (92): The share price has been relatively steady.

Revisions (39): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AYTU stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AYTU, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Jan 26Apr 26Jul 26Oct 26AYTUHigh $15.00Median $7.00Low $7.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $7.00Median $7.00High $15.00

The green dot is the last close — the median target sits +241.5% from it.

Recent analyst actionsNewest first

Of the 18 most recent actions, 2 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
30 Sept 2026Ascendiant CapitalMaintainsBuy$15 → $15
11 June 2026Ascendiant CapitalMaintainsBuy—
11 June 2026Ascendiant CapitalMaintainsBuy$14 → $15
10 Dec 2025Ascendiant CapitalMaintainsBuy—
25 Sept 2025Ascendiant CapitalMaintainsBuy—
25 Sept 2025Maxim GroupMaintainsBuy—
1 July 2025Lake StreetInitiatesBuy—
30 June 2025Ascendiant CapitalInitiatesBuy—
9 Aug 2023Maxim GroupInitiatesBuy—
31 May 2023HC Wainwright & Co.ReiteratesBuy—
21 July 2022HC Wainwright & Co.MaintainsBuy$11 → $6.00
17 May 2022Cantor FitzgeraldMaintainsOverweight$11 → $5.00
28 Apr 2022HC Wainwright & Co.MaintainsBuy$24 → $11
30 Mar 2021Cantor FitzgeraldInitiatesOverweight—
25 Nov 2020HC Wainwright & Co.InitiatesBuy—
25 Nov 2020Northland SecuritiesInitiatesOutperform—
29 May 2020HC Wainwright & Co.InitiatesBuy—
22 Oct 2018Northland SecuritiesInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AYTU appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

AYTU vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 7 Oct 2026, Aytu Biopharma, Inc. returned −13.1% against +17.4% for the S&P 500, dividends included.

AYTU vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120Jan 26Apr 26Jul 26Oct 26AYTUS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AYTU analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Aytu Biopharma, Inc. (AYTU) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.9×

Cheaper than 82% of US stocks

Price / sales
0.4×

Cheaper than 86% of US stocks

Price / book
0.6×

Cheaper than 82% of US stocks

EV / EBITDA
−3.2×

Cheaper than 76% of US stocks

Growth & margins
Revenue growth (YoY)
6.4%

Higher than 42% of US stocks

Earnings growth (YoY)
−32.7%

Higher than 15% of US stocks

Gross margin
61.2%

Higher than 74% of US stocks

Operating margin
−4.8%

Higher than 27% of US stocks

Net margin
−24.8%

Higher than 14% of US stocks

Returns & dividend
Return on equity
−52.6%

Higher than 21% of US stocks

Return on assets
−4.5%

Higher than 32% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Aytu Biopharma, Inc. (AYTU) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Aytu Biopharma, Inc. has a market value of $22.3M and an enterprise value of $14.1M.

  • Revenue in the twelve months to 31 Mar 2026: $56.6M. The latest quarter grew 6.4% year on year.

  • Net income over the same four quarters: −$34.1M, a −60.2% net margin.

  • Free cash flow in the twelve months to 31 Mar 2026: −$1.4M, after $34K of capital spending.

  • Shares outstanding: 10.7M.

  • Trailing P/E: −0.9×; forward P/E: 13.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Aytu Biopharma, Inc. employs 75 people — $755K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

AYTU vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
AYTUAytu Biopharma, Inc.$22.3M
88
UPCUniverse Pharmaceuticals, Inc.$21.6M
32
SHPHShuttle Pharmaceuticals Holdings, Inc.$22.4M
17
TXMDTherapeuticsMD, Inc.$23.1M
78
OPTHOptimi Health Corp.$23.7M
10
RMTIRockwell Medical, Inc.$32.4M
53
ZYBTZhengye Biotechnology Holding Ltd.$34.5M
44

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Aytu Biopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AYTU news & analysis

Elite Pharmaceuticals vs. Aytu: Which CNS Stock Is the Better Buy?

Zacks Investment Research · 7 Oct 2026neutral

A Zacks Investment Research headline compares Elite Pharmaceuticals (ELTP) and Aytu Biopharma (AYTU), noting differences in their CNS portfolios, growth drivers and valuations. The excerpt poses which company appears better positioned but does not provide an answer.

Why it matters — AYTU watchers may find the comparison relevant because it examines the company’s CNS portfolio, growth drivers and valuation alongside a peer.

Aytu BioPharma, Inc. (AYTU) Q4 2026 Earnings Call Transcript

Seeking Alpha · 22 Sept 2026neutral

Aytu BioPharma, Inc. released the transcript of its Q4 2026 earnings call, as published by Seeking Alpha. The transcript covers the company's fourth-quarter 2026 financial results and earnings discussion.

Why it matters — AYTU watchers would care because earnings call transcripts provide direct management commentary on the company's quarterly performance and outlook.

Aytu BioPharma, Inc. (AYTU) Reports Q4 Loss, Beats Revenue Estimates

Zacks Investment Research · 22 Sept 2026positive

Aytu BioPharma reported a fiscal fourth-quarter loss of $0.05 per share, which was narrower than the Zacks Consensus Estimate of a $0.22 loss and improved from the $0.26 per share loss a year earlier. The company also beat revenue estimates.

Why it matters — AYTU watchers would care because the company's quarterly loss came in well below analyst expectations and improved from the prior-year period, signaling better-than-anticipated financial performance.

Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results

Accesswire · 22 Sept 2026positive

Aytu BioPharma reported its fiscal 2026 full year and fourth quarter financial and operational results on September 22, 2026. Fourth quarter net revenue rose 6.4% to $16.1 million with Adjusted EBITDA of $0.5 million, EXXUA generated $6.6 million in net revenue for fiscal 2026, and the company held a $26.3 million cash balance at June 30, 2026. EXXUA fourth-quarter prescriptions totaled 3,323, up about 138% from the prior quarter.

Why it matters — For AYTU watchers, the results highlight growing EXXUA momentum with a sharp prescription increase and a profitable quarter, alongside a solid cash position, offering a view of the company's fiscal trajectory.

Aytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026

Accesswire · 16 Sept 2026neutral

Aytu BioPharma announced it will report its fiscal 2026 full-year and fourth-quarter operational and financial results after market close on September 22, 2026. The company has scheduled a conference call and webcast for 4:30 p.m. that same day.

Why it matters — AYTU watchers will be able to learn the company's operational and financial performance for fiscal 2026 when results are released on September 22.

FAQ

Frequently asked questions about AYTU stock

What is the AYTU stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Aytu Biopharma, Inc. have a median 12-month price target of $7, with estimates ranging from $7 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AYTU stock a buy right now?

Of the 3 analysts covering Aytu Biopharma, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aytu Biopharma, Inc. 88 out of 100 across roughly 4,600 US stocks as at 7 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AYTU?

As at 7 Oct 2026, Aytu Biopharma, Inc. ranks 88 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (92 of 100).

Will AYTU stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +241.5% from the last close, and Ticker Nerd's factor model ranks Aytu Biopharma, Inc. 88 out of 100 as at 7 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AYTU stock forecast for 2030?

No analyst covering Aytu Biopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AYTU are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $15 over the next 12 months.

How has AYTU stock performed over the past year?

Aytu Biopharma, Inc. returned -13.1% over the 12 months to 7 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Aytu Biopharma, Inc. do?

Aytu BioPharma, Inc. is a specialty pharmaceutical company focused on prescription therapeutics and consumer health products.

What is the latest news on AYTU?

The most recent item we track (Zacks Investment Research, 7 Oct 2026): "Elite Pharmaceuticals vs. Aytu: Which CNS Stock Is the Better Buy?". A Zacks Investment Research headline compares Elite Pharmaceuticals (ELTP) and Aytu Biopharma (AYTU), noting differences in their CNS portfolios, growth drivers and valuations. The excerpt poses which company appears better positioned but does not provide an answer.

Company

About Aytu Biopharma, Inc.

Aytu BioPharma, Inc. is a specialty pharmaceutical company focused on prescription therapeutics and consumer health products. Aytu BioPharma primarily serves patients with complex central nervous system conditions, with products used in the treatment of major depressive disorder and attention deficit-hyperactivity disorder. Its current portfolio also includes medicines for allergic conditions and fluoride-based pediatric supplement products for infants and children. The company markets its prescription products through third-party channels and also offers consumer health items directly to consumers. Based in Denver, Colorado, Aytu BioPharma operates as a commercial-stage healthcare company with a portfolio aimed at addressing ongoing medical needs across psychiatry, pediatrics, and supportive care.

CEO Mr. Joshua R. Disbrow · 75 employees · United States · https://aytubio.com